Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue 3, 2008, Pages 219-224

  Jones, Kelsey D J ^a   Hesketh, Therese ^a   Yudkin, John ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug resistance; Drug sensitivity testing; Multidrug resistant tuberculosis; Public health; Therapeutics; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

AFRICA; BACTERIAL STRAIN; CLINICAL TRIAL; COMMUNITY; DISEASE TRANSMISSION; EASTERN EUROPE; EPIDEMIC; FATALITY; HUMAN; INCIDENCE; MEDICAL RESEARCH; MULTIDRUG RESISTANCE; MYCOBACTERIUM; NONHUMAN; PHENOTYPE; PUBLIC HEALTH; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SOUTH AFRICA; TUBERCULOSIS;

AFRICA SOUTH OF THE SAHARA; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 39149145827     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2007.11.014     Document Type: Review

References (55)

1. Aziz M.A., Wright A., Laszlo A., De Muynck A., Portaels F., Van Deun A., Wells C., Nunn P., Blanc L., and Raviglione M. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368 (2006) 2142-2154
2. Billington O.J., McHugh T.D., and Gillespie S.H. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43 (1999) 1866-1869
3. Blower S.M., and Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 10 (2004) 1111-1116
4. Centers for Disease Control Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. Morb. Mortal. Wkly Rep. 55 (2006) 301-305
5. Cohen T., and Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 10 (2004) 1117-1121
6. Cohen T., Sommers B., and Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Inf. Dis. 3 (2003) 13-21
7. Corbett E.L., Marston B., Churchyard G.J., and De Cock K.M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367 (2006) 926-937
8. Dahle U.R. Extensively drug resistant tuberculosis: beware patients lost to follow-up. BMJ 333 (2006) 705
9. Davies A.P., Billington O.J., Bannister B.A., Weir W.R., McHugh T.D., and Gillespie S.H. Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J. Infect. 41 (2000) 184-187
10. Donald P.R., Sirgel F.A., Venter A., Parkin D.P., Seifart H.I., van de Wal B.W., Maritz J.S., and Fourie P.B. Early bactericidal activity of antituberculosis agents. Expert Rev. Anti. Infect. Ther. 1 (2003) 141-155
11. Dye C., Williams B.G., Espinal M.A., and Raviglione M.C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295 (2002) 2042-2046
12. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., Baez J., Kochi A., Dye C., and Raviglione M.C. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283 (2000) 2537-2545
13. Espinal M.A., Laserson K., Camacho M., Fusheng Z., Kim S.J., Tlali R.E., Smith I., Suarez P., Antunes M.L., George A.G., Martin-Casabona N., Simelane P., Weyer K., Binkin N., and Raviglione M.C. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis. 5 (2001) 887-893
14. Feuer, C., 2006. Tuberculosis Research & Development: a Critical Analysis, second ed. Syed, J., Harrington, M., Huff, B. (Eds). Treatment Action Group, New York. http://www.stoptb.org/researchmovement/assets/documents/tbrandd2.pdf [accessed November 2007].
15. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., and Bohannan B.J. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312 (2006) 1944-1946
16. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., Zeller K., Andrews J., and Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (2006) 1575-1580
17. Gillespie S.H., Billington O.J., Breathnach A., and McHugh T.D. Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts. Microb. Drug Resist. 8 (2002) 273-279
18. Gillespie S.H., Basu S., Dickens A.L., O'Sullivan D.M., and McHugh T.D. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J. Antimicrob. Chemother. 56 (2005) 344-348
19. Guillerm, M., Usdin, M., Arkinstall, J., 2006. Tuberculosis Diagnosis and Drug Sensitivity Testing. An Overview of the Current Diagnostic Pipeline. Médecins Sans Frontières, Paris.
20. Gupta R., Cegielski J.P., Espinal M.A., Henkens M., Kim J.Y., Lambregts-van Weezenbeek C.S.B., Lee J.W., Raviglione M.C., Suarez P.G., and Varaine F. Increasing transparency in partnership for health - Introducing the Green Light Committee. Trop. Med. Int. Health 7 (2002) 970-976
21. Han L.L., Sloutsky A., Canales R., Naroditskaya V., Shin S.S., Seung K.J., Timperi R., and Becerra M.C. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int. J. Tuberc. Lung Dis. 9 (2005) 818-821
22. Hane F., Thiam S., Fall A.S., Vidal L., Diop A.H., Ndir M., and Lienhardt C. Identifying barriers to effective tuberculosis control in Senegal: an anthropological approach. Int. J. Tuberc. Lung Dis. 11 (2007) 539-543
23. Johnson R., Warren R., Strauss O.J., Jordaan A.M., Falmer A.A., Beyers N., Schaaf H.S., Murray M., Cloete K., van Helden P.D., and Victor T.C. An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the western Cape, South Africa. Int. J. Tuberc. Lung Dis. 10 (2006) 1412-1414
24. Joseph P., Severe P., Ferdinand S., Goh K.S., Sola C., Haas D.W., Johnson W.D., Rastogi N., Pape J.W., and Fitzgerald D.W. Multidrug-resistant tuberculosis at an HIV testing center in Haiti. AIDS 20 (2006) 415-418
25. Kam K.M., and Yip C.W. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus. Int. J. Tuberc. Lung Dis. 8 (2004) 760-766
26. Kapp C. XDR tuberculosis spreads across South Africa. Lancet 369 (2006) 729
27. Keshinro B., and Diul M.Y. HIV-TB: epidemiology, clinical features and diagnosis of smear-negative TB. Trop. Doct. 36 (2006) 68-71
28. Masjedi M.R., Farnia P., Sorooch S., Pooramiri M.V., Mansoori S.D., Zarifi A.Z., Akbarvelayati A., and Hoffner S. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin. Infect. Dis. 43 (2006) 841-847
29. Mbulo G.M., Kambashi B.S., Kinkese J., Tembwe R., Shumba B., Godfrey-Faussett P., and McNerny R. Comparison of two bacteriophage tests and nucleic acid amplification for the diagnosis of pulmonary tuberculosis in sub-Saharan Africa. Int. J. Tuberc. Lung Dis. 8 (2004) 1342-1347
30. McGreal, C., Boseley, S., 2007. The dilemma of a deadly disease: patients may be forcibly detained. Guardian, Tuesday January 23, 2007. http://www.guardian.co.uk/frontpage/story/0,1996612,00.html [accessed November 2007].
31. Mitnick C., Bayona J., Palacios E., Shin S., Furin J., Alcantara F., Sanchez E., Sarria M., Becerra M., Fawzi M.C., Kapiga S., Neuberg D., Maguire J.H., Kim J.Y., and Farmer P. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348 (2003) 119-128
32. Moore D.A., Evans C.A., Gilman R.H., Caviedes L., Coronel J., Vivar A., Sanchez E., Pinedo Y., Saravia J.C., Salazar C., Oberhelman R., Hollm-Delgado M.G., LaChira D., Escombe A.R., and Friedland J.S. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355 (2006) 1539-1550
33. Nathanson E., Lambregts-van Weezenbeek C., Rich M.L., Gupta R., Bayona J., Blöndal K., Caminero J.A., Cegielski J.P., Danilovits M., Espinal M.A., Hollo V., Jaramillo E., Leimane V., Mitnick C.D., Mukherjee J.S., Nunn P., Pasechnikov A., Tupasi T., Wells C., and Raviglione M.C. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis. 12 (2006) 1389-1397
34. Oliveira-Cruz V., Kurowski C., and Mills A. Delivery of priority health services: Searching for synergies within the vertical versus horizontal debate. J. Int. Dev. 15 (2003) 67-86
35. Olle-Goig J.E., and Sandy R. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus. Int. J. Tuberc. Lung. Dis. 9 (2005) 765-770
36. Perrin F.M.R., Lipman M.C.I., McHugh T.D., and Gillespie S.H. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect. Dis. 7 (2007) 481-490
37. Prammananan T., Arjratanakool W., Chaiprasert A., Tingtoy N., Leechawengwong M., Asawapokee N., Leelarasamee A., and Dhiraputra C. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int. J. Tuberc. Lung Dis. 9 (2005) 216-219
38. Reid A., Scano F., Getahun H., Williams B., Dye C., Nunn P., De Cock K.M., Hankins C., Miller B., Castro K.G., and Raviglione M.C. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect. Dis. 6 (2006) 483-495
39. Robert J., Trystram D., Truffot-Pernot C., and Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. Eur. Respir. J. 22 (2003) 833-837
40. Ruddy M., Balabanova Y., Graham C., Fedorin I., Malomanova N., Elisarova E., Kuznetznov S., Gusarova G., Zakharova S., Melentyev A., Krukova E., Golishevskaya V., Erokhin V., Dorozhkova I., and Drobniewski F. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 60 (2005) 130-135
41. Sharma S.K., and Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 130 (2006) 261-272
42. Spigelman M., and Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 367 (2006) 945-947
43. Telles M.A., Ferrazoli L., Waldman E.A., Giampaglia C.M., Martins M.C., Ueki S.Y., Chimara E., Silva C.A., Cruz V., Waldman C.C., Heyn I., Hirono I.U., and Riley L.W. A population-based study of drug resistance and transmission of tuberculosis in an urban community. Int. J. Tuberc. Lung Dis. 9 (2005) 970-976
44. Timperi R., Han L.L., Sloutsky A., Becerra M.C., Nardell E.A., Salazar J.J., and Smith-Fawzi M.C. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int. J. Tuberc. Lung Dis. 9 (2005) 175-180
45. Torun T., Gungor G., Ozmen I., Bolukbasi Y., Maden E., Bicakci B., Atac G., Sevim T., and Tahaoglu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 9 (2005) 1373-1377
46. Toungoussova O.S., Mariandyshev A.O., Bjune G., Caugant D.A., and Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 202-206
47. WHO, 2000. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, Geneva, WHO/CDS/TB/2000.279.
48. WHO, 2003. Treatment of tuberculosis: guidelines for national programmes. World Health Organization, Geneva, WHO/CDS/STB/2003.313.
49. WHO, 2006a. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. World Health Organization, Geneva, WHO/HTM/TB/2006.362.
50. WHO. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol. Rec. 81 (2006) 408
51. WHO, 2007. The global MDR-TB & XDR-TB response plan 2007-2008. World Health Organization, Geneva, WHO/HTM/TB/2007.387.
52. WHO/IUATLD, 1997. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. World Health Organization, Geneva, WHO/TB/97.229.
53. WHO/IUATLD, 2000. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Dug Resistance Surveillance. Report 2: Prevalence and Trends. World Health Organization, Geneva, WHO/CDS/TB/2000.278.
54. Yong K.J., Shakow A., Mate K., Vanderwarker C., Gupta R., and Farmer P. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Soc. Sci. Med. 61 (2005) 847-859
55. Zignol M., Hosseini M.S., Wright A., Weezenbeek C.L., Nunn P., Watt C.J., Williams B.G., and Dye C. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194 (2006) 479-485